Whitehawk Therapeutics, Inc. (NASDAQ:WHWK) Short Interest Up 139.9% in June

Posted by Geri Gentry on Jul 15th, 2026

Whitehawk Therapeutics, Inc. (NASDAQ:WHWK – Get Free Report) was the target of a significant growth in short interest during the month of June. As of June 30th, there was short interest totaling 2,833,866 shares, a growth of 139.9% from the June 15th total of 1,181,288 shares. Based on an average trading volume of 824,119 shares, the short-interest ratio is currently 3.4 days. Approximately 11.4% of the company’s shares are sold short.

Whitehawk Therapeutics Trading Up 0.9%

WHWK traded up $0.04 during trading on Wednesday, hitting $3.85. 99,700 shares of the company’s stock were exchanged, compared to its average volume of 299,302. Whitehawk Therapeutics has a 1 year low of $1.57 and a 1 year high of $5.49. The stock has a 50 day moving average price of $4.27 and a 200 day moving average price of $3.62. The firm has a market cap of $190.14 million, a P/E ratio of -2.29 and a beta of 0.77.

Whitehawk Therapeutics (NASDAQ:WHWK – Get Free Report) last issued its earnings results on Thursday, May 7th. The company reported ($0.32) EPS for the quarter, beating analysts’ consensus estimates of ($0.36) by $0.04. Analysts forecast that Whitehawk Therapeutics will post -1.37 earnings per share for the current fiscal year.

Analysts Set New Price Targets

A number of equities analysts have weighed in on WHWK shares. B. Riley Financial initiated coverage on shares of Whitehawk Therapeutics in a research note on Thursday, June 25th. They set a “buy” rating and a $10.00 price target on the stock. Oppenheimer restated an “outperform” rating and set a $7.00 price objective on shares of Whitehawk Therapeutics in a report on Friday, May 8th. Citigroup started coverage on Whitehawk Therapeutics in a research report on Thursday, April 16th. They issued an “outperform” rating on the stock. Citizens Jmp assumed coverage on Whitehawk Therapeutics in a report on Thursday, April 16th. They issued a “market outperform” rating and a $8.00 target price on the stock. Finally, Leerink Partners assumed coverage on Whitehawk Therapeutics in a research report on Monday. They set an “outperform” rating and a $9.00 price target for the company. Six research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $8.20.

View Our Latest Stock Report on Whitehawk Therapeutics

Insider Activity

In related news, CFO Scott M. Giacobello sold 141,600 shares of the business’s stock in a transaction that occurred on Thursday, April 16th. The shares were sold at an average price of $4.13, for a total value of $584,808.00. Following the completion of the sale, the chief financial officer directly owned 295,224 shares in the company, valued at approximately $1,219,275.12. The trade was a 32.42% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Corporate insiders own 49.90% of the company’s stock.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently modified their holdings of the stock. Vanguard Group Inc. acquired a new stake in shares of Whitehawk Therapeutics in the third quarter valued at about $2,552,000. Dimensional Fund Advisors LP acquired a new position in Whitehawk Therapeutics during the 3rd quarter worth approximately $84,000. Squarepoint Ops LLC purchased a new position in Whitehawk Therapeutics in the 3rd quarter worth approximately $159,000. Bridgeway Capital Management LLC purchased a new position in Whitehawk Therapeutics in the 3rd quarter worth approximately $409,000. Finally, Acuta Capital Partners LLC acquired a new stake in Whitehawk Therapeutics in the third quarter valued at approximately $6,480,000. Institutional investors and hedge funds own 52.08% of the company’s stock.

About Whitehawk Therapeutics

(Get Free Report)

Aadi Bioscience, Inc, a clinical-stage biopharmaceutical company, engages in developing and commercializing precision therapies for genetically defined cancers with alterations in mTOR pathway genes. Its lead drug candidate, FYARRO is a form of sirolimus bound to albumin. Aadi is evaluating FYARRO in cancers with known mTOR pathway activation, including tumor agnostic indications targeting specific genomic alterations that activate the mTOR pathway. The company was incorporated in 2007 and is headquartered in Pacific Palisades, California.